NCT03261401View on ClinicalTrials.gov

First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

June 14, 2019

Study Completion Date

June 14, 2019

Conditions
Healthy
Interventions
DRUG

M5717

Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

DRUG

Placebo

Participants received placebo matched to M5717

DRUG

M5717

Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Trial Locations (1)

Unknown

Q-Pharm Pty Ltd, Brisbane

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03261401 - First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants | Biotech Hunter | Biotech Hunter